Home
News
Create
Screeners
Insights
Godavari Drugs
124.
65
+2.65
(+2.17%)
Market Cap
₹126.28 Cr
PE Ratio
30.20
Industry
Healthcare
Buy
Sell
Company Performance:
1D
+2.17%
1M
-1.66%
6M
+51.18%
1Y
+32.20%
5Y
+105.69%
View Company Insights
Latest news about Godavari Drugs
Godavari Drugs closes trading window for Q1FY27 results
1 day ago
Godavari Drugs Limited has closed its trading window from July 1, 2026, until 48 hours after the Q1FY27 results declaration, complying with SEBI regulations to prevent insider trading.
Godavari Drugs reports FY26 net profit of ₹408.91 lakh
May 28, 2026
Godavari Drugs Limited Submits SEBI Compliance Certificate for Q4FY26
Apr 08, 2026
Godavari Drugs: Prashant Shrimal Files SEBI Disclosure for Share Acquisition
Mar 23, 2026
Godavari Drugs Limited Shareholders Approve Preferential Equity Share and Convertible Warrant Issuance at EGM
Feb 12, 2026
More news about Godavari Drugs
11
Feb 26
Godavari Drugs Reports Q3FY26 Results, Approves ₹5.50 Crore Working Capital Loan
Godavari Drugs reported Q3FY26 net profit of ₹75.76 lakhs on revenue of ₹2218.43 lakhs, showing decline from previous year's ₹76.74 lakhs profit and ₹2955.21 lakhs revenue. Nine-month performance also declined with net profit at ₹279.84 lakhs versus ₹348.69 lakhs last year. The Board approved a ₹5.50 crore short-term working capital loan from ICICI Bank with 6-month tenure for new order execution requirements.
15
Jan 26
Godavari Drugs Board Approves Preferential Issue of Convertible Warrants and Equity Shares Worth ₹44.12 Crores
Godavari Drugs Limited board approved preferential issue of 23,60,065 convertible warrants and 25,96,935 equity shares at ₹89 each, raising approximately ₹44.12 crores. The warrants are exclusively for 9 promoters with 18-month conversion period, while equity shares target 31 investors including promoters and non-promoters. Post-allotment shareholding will be 51.52% promoters and 48.48% public, subject to shareholder approval in EGM scheduled February 12, 2026.
08
Jan 26
Godavari Drugs Limited Issues Clarification on Share Price Movement to BSE
Godavari Drugs Limited submitted a clarification to BSE on January 8, 2026, regarding significant share price movement, confirming no unpublished price sensitive information exists. The company attributed the price volatility to market-driven demand-supply factors and reaffirmed its commitment to regulatory compliance under SEBI regulations.
Godavari Drugs
124.
65
+
2.
65
(+
2.
17
%)
1 Year Returns:
+32.20%
Industry Peers
Sun Pharmaceutical
1,874.40
(+
0.
34
%)
Divis Laboratories
6,753.50
(+
0.
10
%)
Torrent Pharmaceuticals
4,504.40
(-
0.
21
%)
Cipla
1,437.90
(+
0.
33
%)
Dr Reddys Laboratories
1,328.40
(+
2.
08
%)
Zydus Life Science
1,099.30
(-
1.
16
%)
Lupin
2,367.60
(+
0.
42
%)
Mankind Pharma
2,483.00
(-
1.
80
%)
Aurobindo Pharma
1,530.60
(-
0.
23
%)
Laurus Labs
1,454.20
(-
1.
81
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO
Cyclical Trend
Events Calendar